Particular attention is paid to the release of the active ingredients of drugs in the form of tablets. Therefore, we have developed a method for determining the dissolution test, for the original drug Hypertril. The purpose. To develop a methodology for dissolution test for Hypertril tablets with an active substance content of 20 mg using the HPLC method. Materials and methods. In the studies we used Hypertril tablets with an active substance content of 20 mg, obtained in the Standardization and Drug Technology Laboratory at the Pharmaceutical Chemistry Department of ZSMU. A standard sample of the hypertril substance was received from the State Enterprise “Chemical Reagents Plant” (Kharkiv, Ukraine). We used high-performance liquid chromatograph Bishoff with an UV detector for studies. During the dissolution test of the Hypertril tablets, a device with a blade from the company Pharma Test PTWS 120D, Germany, was used. Results. As a result of the conducted studies, the chromatograms were obtained. Having analyzed the chromatograms, we proved that the method is highly sensitive and accurate and can be used to determine the dissolution test. The obtained study results showed that the amount of the active substance that passed into the solution from the Hypertril tablets after 45 minutes and is from 91.2 to 99.6 %, that meets the requirements of the State Pharmacopoeia of Ukraine. Conclusions. In the course of study, we developed a method for carrying out the dissolution test for Hypertril tablets with an active substance content of 20 mg using the HPLC method. The study results confirm that the developed method is accurate and reliable.

L.I.Kucherenko, N.V.Parnyuk, Z.B.MoryakDEVELOPMENT OF QUANTITATIVE DETERMINATION METODS FOR THE STEPWISE CONTROL OF "HYPERTRIL" TABLETS PRODUCTIONZaporizhzhia State Medical University“Pharmatron” Scientific-and-Production CorporationKey words: hypertril, tablet mass, tablets, spectrophotometry IntroductionLast 20-25 years inUkraineare characterized by unfavorable demographic situation, a significant increase in morbidity and mortality. The deterioration ofUkrainepopulation health is often caused by cardiovascular diseases. Therefore, the development of treatments for diseases of the cardiovascular system is the actual problem of modern medicine and pharmacy. This led to the creation of fundamentally new antianginal and antihypertensive medication of original structure, which will have a minimum of side effects. At the Department of Pharmaceutical Chemistry of Zaporizhzhia State Medical University in collaboration with the SPC "Pharmatron" under the direction of Professor Mazur I.A, a new original compound - bromide 1-β-phenylethyl-4-amino-1,2,4-triazole (hypertril) is received and shows antihypertensive, antiischemic and antioxidant properties. Most drugs for the treatment of cardiovascular disease are used in pill form. Therefore, the new elected rational drug dosage form is a pill.The aim of research Development of methods of standardization, in particular quantitative content of hypertril in tablet weight by physical and chemical methods.Materials and methods During technological research a drug (pill average weight0.15 grams) containing0.02 gof active substance, was developed. During the stepwise control of pill's production the greatest attention is paid to quality control of tablet weight. One of the most modern methods of pharmaceutical analysis is instrumental methods, including spectral one.Results and discussion During previous studies, we have developed a method of spectrophotometric determination of hypertril substance. The studies showed that the absorption curves in the UV region of our and standard designs are identical and absorption maxima coincide. For the qualitative and quantitative determination of hypertril in tablet weight, a spectrophotometric determination method was approbated. Also it was developed and used to standardize hypertril substance.Identification of the substance in hypertril tablet weight by spectrophotometry. We measure the optical spissitude of the prepared solution of hypertril tablet weight.Preparation of standard solution (comparison solution). We measure the optical spissitude of the standard sample at a wavelength λ = 258 nm. As a standard substance we use hypertril sample (state owned enterprise "Plant of chemical reagent" of Science and Technology Complex "Institute for Single Crystals " NAS of Ukraine), which meets the requirements of quality control methods. Terms of spectrophotometric determination.Optical spissitude measurement of solutions was held by scanning spectrophotometer Optizen POP, relatively solvent water, the thickness of the cuvette -1 cm, wavelength λ = 258 nm. As a result of our research the methodology of standardization of hypertril in tablet weight was designed by spectrophotometry method that is simple and easy in execution, replicable and meets all the requirements of the State Pharmacopoeia and international standards.Findings As a result of research, we developed a sensitive, objective, reliable and reproducible method for the spectrophotometric determination of hypertril in the tablet mass.ReferencesBelenichev I.F., Kucherenko L.I., Volchik Yu.A., Abramov A.V., Buhtiyarova N.V. Some aspects of cardioprotective activity of new b-adrenoblocker with NO-mimetic effect «Hypertril» on myocardial infarction model. Farmakologiya ta likarska toksikologiya 2014; 4–5 (40): 11-16Georgievskiy G.V. Development of the complex physical and chemical methods, ensuring the creation and control of the quality of the original domestic products, 1,2,4-triazole. Zaporozhskiy meditsinskiy zhurnal 2011; 13(1): 58–69.Derzhavna Farmakopeia Ukrainy [State Ukrainian Pharmacopeia]. Kharkiv, 2; 2008: 620.Kucherenko L.I., Hromilova O.V., Moryak Z.B., Tkachenko G.I., Vaschenko O.V. Stage control of tablets manufacturing. Aktualni pitannya farmatsevtichnoi i medichnoi nauki ta praktiki 2014; #2: 31-34.5. Mazur I.A, Belenichev I.F., Chekman I.S. Using 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide (Hypertril) as an active base of drug preparations for correcting dysfunctions of the nitroxydergic system of target organs accompanying homocysteinemia and acute cerebrovascular disorders. Patent RU 2 532 394, 2013.Mazur I.A, Belenichev I.F., Chekman I.S. Using of 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide as an active bast of medical agents for correction of nitroxidergic system dysfunction atherosclerosis and diabetes mellitus. Patent UA 84351, 2013Mazur I.A., Chekman I.S., Belenichev I.F., Voloshin N.A. Metabolitotropnyie preparati. Zaporozhe, 2007: 304.European Pharmacopoeia.Strasbourg: Сouncil ofEurope 2007: 1100.Sevgi T.U.,Fikriye T.E. Spectrophotometric method for the determination, validation, spectroscopic and thermal analysis of diphenhydramine in pharmaceutical preparation. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2010; 77: 324–329.White W. Blood pressure monitoring in cardiovascular medicine and therapeutics.New Jersey: Humana Press 2011: 308.

Chronic (15 days) single daily intraperitoneal insertion of the new preparation MT (5 mg/kg) and metoprolol (10 mg/kg) into SHR rats leads to the same decrease (18%) in arterial pressure. In addition, MT exhibits a cardioprotective effect because of NO-mimetic properties, increasing NO formation in myocardium via increasing general NOS activity and eNOS expression. MT normalizes iNOS expression in myocardium mitochondria and decreases nitrotyrosine (nitrosation stress marker) formation. At the same time, the reference preparation metoprolol did not exhibit NO-mimetic properties in myocardium of SHR rats.